Clinical Trial Update: Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus [Phase 3]

View source ↗

Summary

Phase 3 trial comparing passive immunization with TNM002 Injection to human tetanus immunoglobulin for tetanus prophylaxis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tetanus

Drugs mentioned

• Human tetanus immunoglobulin (tetanus immunoglobulin)
• TNM002 Injection (TNM002)

Snippet

Sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd. | Conditions: Tetanus | Phase 3 | Status: COMPLETED